The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 drug alert for Caspofungin 70mg powder for concentrate for solution for infusion. Cadiasun Pharma GmBH has advised that there is an error on the patient information leaflet for Caspofungin 70mg powder for concentrate for solution for infusion. There is also an error in the Summary of Product Characteristics (SmPC).
Further details of the alert, the affected batches, and action to take are available on the MHRA website.